central venous catheter (CVC) sets
Mallinckrodt Sells Immunotherapy Business to CVC Capital for $925 Million
Mallinckrodt, CVC Capital, immunotherapy, Therakos, $925 million deal
Mallinckrodt to Sell Therakos Business Unit to CVC Capital for $925 Million
Mallinckrodt, Therakos, CVC Capital Partners, photopheresis, extracorporeal photopheresis, ECP, cutaneous T-cell lymphoma, CTCL, immunotherapy, pharmaceuticals, medical technology, healthcare services